必威体育登录手机Agilent Technologies Thought Leader Award Supports Institut Curie, Dr.Emmanuel Barillot's Web-Based Tools for Cancer and Drug-Safety Research
SANTA CLARA, Calif., Aug.27, 2013
必威体育登录手机Agilent Technologies Inc.(NYSE: A) today announced that Dr.必威体育登录手机Emmanuel Barillot, director of Bioinformatics and Systems IT at the Institut Curie in Paris, has received an Agilent Thought Leader Award in recognition of his pioneering development of user-friendly, Web-based bioinformatics tools for systems toxicology.
The award will support Dr.Barillot's work in developing a database of cellular signaling pathways and a visualization tool to help the pharmaceutical industry develop more effective cancer treatments.
The new Web-based visualization tool will augment the institute'sAtlas of Cancer Signaling Networksand will be further enhanced by the combined capabilities of Curie'sNaviCell必威体育登录手机mapping tool and Agilent's GeneSpring software and NMR technologies.Together, these tools will enable researchers to identify off-pathway effects that could lead to undesirable outcomes, such as DNA damage.
必威体育登录手机"Assessing the safety and potential toxicity of drug candidates is a significant hurdle in the extraordinarily complex, labor-intensive drug development process," said Tony Owen, Agilent's senior director of life science marketing and market development."Pharmaceutical companies can spend many years and billions of dollars only to find that a once-promising preclinical therapeutic compound is actually harmful to patients in clinical tests.It is incumbent upon drug developers to find ways to assess drug toxicity much earlier in the process to reduce R&D time, minimize costs and maximize patient benefits."
必威体育登录手机"The Agilent Thought Leader Award will accelerate the further development of the Curie Atlas of Cancer Signaling Networks, a comprehensive and freely available cancer pathway database, and NaviCell network visualization tool," said Dr.Barillot."These tools will enable earlier identification and visualization of toxic interactions between signaling pathways during the discovery and development of therapeutics for the treatment of cancer, thus enabling better informed drug-candidate selection and prioritization.They will also be useful for interpreting high-throughput biological data, like next-generation sequencing profiles of tumors or other samples."
必威体育登录手机Agilent Thought Leader Awards recognize leading researchers in the areas of synthetic biology, structural biology, systems toxicology, integrated biology, the individual "omics" and the detection of contaminants in environmental matrices.The awards promote fundamental advancements by contributing financial support, measurement solutions and expertise to recipient research.必威体育登录手机Agilent is committed to developing new applications and products for life science and chemical analysis research in these areas.Information about previous recipients is available at:必威体育登录手机www.dayu-jc.com/univ_relation/TLP/index.shtml.
About the Institut Curie
The Institut Curie comprises the largest oncology research center and two state-of-the-art hospitals in France.A pioneer of many cancer treatments, the Institut Curie is a center of excellence for the treatment of breast cancer, pediatric tumors and ocular tumors, and is responsible for medical and scientific innovations in France and abroad.
Founded in 1909 on a model devised by Marie Curie, the institute has 3,200 researchers, physicians, clinicians, technicians and administrative staff.For more information, visitwww.curie.fr.
必威体育登录手机About Agilent Technologies
必威体育登录手机Agilent Technologies Inc.(NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications.The company's 20,500 employees serve customers in more than 100 countries.必威体育登录手机Agilent had revenues of $6.9 billion in fiscal 2012.必威体育登录手机Information about Agilent is available at必威体育登录手机www.dayu-jc.com.
# # #
For images related to this press release,
please visit the�ImageLibrary (Image #24)
Contact:
Susan Berg
+1 408 553 7093
必威体育登录手机susan_berg1@agilent.com